Characteristics of patient samples
| Patient ID . | Subtype . | Karyotype . | Age at diagnosis (y) . | Sex . | Disease status at biopsy . | MRD status . |
|---|---|---|---|---|---|---|
| 1* | Pre-B | −1 | 2 | F | D | Low |
| 2* | c-ALL | t(12;21) | 7 | F | D | Low |
| 3* | Pre-B | t(1;19) | 4 | F | D | Low |
| 4* | c-ALL | t(9;22), −9 | 7 | M | D | Low |
| 5* | c-ALL | t(12;21) | 8 | F | D | Low |
| 6* | Pre-B | 46 XX | 3 | F | D | Low |
| 7* | c-ALL | t(12;21) | 4 | F | D | Low |
| 8* | c-ALL | Complex | 4 | M | D | Low |
| 9* | c-ALL | t(12;21) | 4 | M | D | Risk |
| 10* | Pre-B | +12,+21 | 2 | M | D | Low |
| 11* | Pre-B | t(9;22) | 15 | M | D | Low |
| 12* | Pre-B | 46 XY | 8 | M | D | Risk |
| 13* | c-ALL | 46 XX | 7 | F | D | Risk |
| 14* | Pre-B | t(12;21) | 4 | F | D | Low |
| 15* | Pre-B | Hyperdiploid | 5 | M | R | N/A |
| 16* | Pre-B | Hyperdiploid | 1 | M | D | Risk |
| 17* | c-ALL | Complex | 5 | M | D | Risk |
| 18* | Pre-B | 46 XY | 7 | F | D | Low |
| 19* | Pre-B | +21 | 2 | M | D | Low |
| 20* | Pre-B | 9p, -21 | 3 | F | D | Low |
| 21* | Pre-B | t(12;21), −12 | 14 | F | D | Low |
| 22 | Pre-B | −9, +10, -18 | 2 | F | D | Risk |
| 23* | c-ALL | t(12;21), −21 | 3 | M | D | Low |
| 24 | Pre-B | +21 | 2 | M | R | Risk |
| 25* | Pre-B | Hyperdiploid | 4 | M | D | Low |
| 26* | c-ALL | Hyperdiploid | 1 | M | D | Low |
| 27 | Pre-B | MLL | 15 | F | D | Risk |
| 28 | Pre-B | t(9;22) | 15 | M | D | Risk |
| 29 | Pre-B | Hyperdiploid | 9 | M | D | Risk |
| 30 | Pre-B | t(12;21) | 6 | F | D | Low |
| 31 | c-ALL | t(12;21) | 5 | F | D | Low |
| 32 | c-ALL | t(9;12) | 3 | F | D | Low |
| 33 | c-ALL | Ph+-like | 5 | F | D | Risk |
| 34 | Pre-B | 46 XX | 17 | F | D | Low |
| 35 | Pro-B | +5 | 16 | M | D | Low |
| 36 | Pre-B | +RUNX1 | 2 | M | D | Low |
| 37 | Pre-B | 46 XX | 16 | F | D | Low |
| 38 | Pre-B | dic(9;20) | 4 | F | D | Low |
| 39 | Pre-B | t(9;15), +6, −13 | 3 | F | D | Low |
| 40 | Pre-B | t(1;19), −13 | 1 | F | D | Low |
| 41 | Pre-B | 46 XX | 4 | F | D | Low |
| 42 | Pre-B | t(12;21) | 2 | M | D | Low |
| 43 | Pre-B | dic(7:9), t(9;14), −20, +21, +3mar | 2 | F | D | Low |
| 44 | Pre-B | iAMP21 | 11 | M | D | Int |
| 45 | Pre-B | t(12;21), −10, +12, −13, +21, +3mar | 5 | M | D | Int |
| 46 | Pre-B | 46 XY | 15 | M | D | Risk |
| 47 | Pro-B | −6 | 4 | M | D | Risk |
| 48 | Pre-B | +RUNX1 | 2 | F | D | Risk |
| 49 | Pre-B | PDGFTB/CSF IR rear, -ETV6 | 8 | F | D | Risk |
| 50 | Pre-B | N/A | 11 | M | D | Risk |
| 51 | Pre-B | t(12;21) | 3 | M | D | Low |
| 52 | Pre-B | -Y, +7, −9, +21, +mar | 3 | M | D | Low |
| 53 | Pre-B | 46 XY | 4 | M | D | Low |
| 54 | Pre-B | t(4;11) | 6 | M | D | Int |
| 55 | Pre-B | t(12;21) | 5 | M | D | Low |
| 56* | Pro-B | i9, −9 | 16 | M | D | Low |
| 57 | Pro-B | t(12;21) | 3 | M | D | Low |
| 58 | Pro-B | Complex | 8 | F | D | Low |
| 59* | Pre-B | t(12;21) | 2 | F | D | Low |
| 60 | Pro-B | N/A | 17 | F | D | Int |
| 61 | Pre-B | Hyperdiploid | 2 | M | D | Low |
| 62 | c-ALL | Hyperdiploid | 7 | M | D | Risk |
| 63 | Pre-B | t(1;19) | 12 | M | D | Low |
| Patient ID . | Subtype . | Karyotype . | Age at diagnosis (y) . | Sex . | Disease status at biopsy . | MRD status . |
|---|---|---|---|---|---|---|
| 1* | Pre-B | −1 | 2 | F | D | Low |
| 2* | c-ALL | t(12;21) | 7 | F | D | Low |
| 3* | Pre-B | t(1;19) | 4 | F | D | Low |
| 4* | c-ALL | t(9;22), −9 | 7 | M | D | Low |
| 5* | c-ALL | t(12;21) | 8 | F | D | Low |
| 6* | Pre-B | 46 XX | 3 | F | D | Low |
| 7* | c-ALL | t(12;21) | 4 | F | D | Low |
| 8* | c-ALL | Complex | 4 | M | D | Low |
| 9* | c-ALL | t(12;21) | 4 | M | D | Risk |
| 10* | Pre-B | +12,+21 | 2 | M | D | Low |
| 11* | Pre-B | t(9;22) | 15 | M | D | Low |
| 12* | Pre-B | 46 XY | 8 | M | D | Risk |
| 13* | c-ALL | 46 XX | 7 | F | D | Risk |
| 14* | Pre-B | t(12;21) | 4 | F | D | Low |
| 15* | Pre-B | Hyperdiploid | 5 | M | R | N/A |
| 16* | Pre-B | Hyperdiploid | 1 | M | D | Risk |
| 17* | c-ALL | Complex | 5 | M | D | Risk |
| 18* | Pre-B | 46 XY | 7 | F | D | Low |
| 19* | Pre-B | +21 | 2 | M | D | Low |
| 20* | Pre-B | 9p, -21 | 3 | F | D | Low |
| 21* | Pre-B | t(12;21), −12 | 14 | F | D | Low |
| 22 | Pre-B | −9, +10, -18 | 2 | F | D | Risk |
| 23* | c-ALL | t(12;21), −21 | 3 | M | D | Low |
| 24 | Pre-B | +21 | 2 | M | R | Risk |
| 25* | Pre-B | Hyperdiploid | 4 | M | D | Low |
| 26* | c-ALL | Hyperdiploid | 1 | M | D | Low |
| 27 | Pre-B | MLL | 15 | F | D | Risk |
| 28 | Pre-B | t(9;22) | 15 | M | D | Risk |
| 29 | Pre-B | Hyperdiploid | 9 | M | D | Risk |
| 30 | Pre-B | t(12;21) | 6 | F | D | Low |
| 31 | c-ALL | t(12;21) | 5 | F | D | Low |
| 32 | c-ALL | t(9;12) | 3 | F | D | Low |
| 33 | c-ALL | Ph+-like | 5 | F | D | Risk |
| 34 | Pre-B | 46 XX | 17 | F | D | Low |
| 35 | Pro-B | +5 | 16 | M | D | Low |
| 36 | Pre-B | +RUNX1 | 2 | M | D | Low |
| 37 | Pre-B | 46 XX | 16 | F | D | Low |
| 38 | Pre-B | dic(9;20) | 4 | F | D | Low |
| 39 | Pre-B | t(9;15), +6, −13 | 3 | F | D | Low |
| 40 | Pre-B | t(1;19), −13 | 1 | F | D | Low |
| 41 | Pre-B | 46 XX | 4 | F | D | Low |
| 42 | Pre-B | t(12;21) | 2 | M | D | Low |
| 43 | Pre-B | dic(7:9), t(9;14), −20, +21, +3mar | 2 | F | D | Low |
| 44 | Pre-B | iAMP21 | 11 | M | D | Int |
| 45 | Pre-B | t(12;21), −10, +12, −13, +21, +3mar | 5 | M | D | Int |
| 46 | Pre-B | 46 XY | 15 | M | D | Risk |
| 47 | Pro-B | −6 | 4 | M | D | Risk |
| 48 | Pre-B | +RUNX1 | 2 | F | D | Risk |
| 49 | Pre-B | PDGFTB/CSF IR rear, -ETV6 | 8 | F | D | Risk |
| 50 | Pre-B | N/A | 11 | M | D | Risk |
| 51 | Pre-B | t(12;21) | 3 | M | D | Low |
| 52 | Pre-B | -Y, +7, −9, +21, +mar | 3 | M | D | Low |
| 53 | Pre-B | 46 XY | 4 | M | D | Low |
| 54 | Pre-B | t(4;11) | 6 | M | D | Int |
| 55 | Pre-B | t(12;21) | 5 | M | D | Low |
| 56* | Pro-B | i9, −9 | 16 | M | D | Low |
| 57 | Pro-B | t(12;21) | 3 | M | D | Low |
| 58 | Pro-B | Complex | 8 | F | D | Low |
| 59* | Pre-B | t(12;21) | 2 | F | D | Low |
| 60 | Pro-B | N/A | 17 | F | D | Int |
| 61 | Pre-B | Hyperdiploid | 2 | M | D | Low |
| 62 | c-ALL | Hyperdiploid | 7 | M | D | Risk |
| 63 | Pre-B | t(1;19) | 12 | M | D | Low |
Patient IDs with an asterisk (*) indicates those treated on UKALL 2003. Patient IDs with no asterisk were treated on UKALL 2011. Low-risk (Low) and risk MRD status was defined at day 29, intermediate-risk (Int) was determined at week 14.
D, diagnosis; F, female; M, male; N/A, not available; R, relapse.